Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus Infection
Conditions
Staphylococcus Aureus Infection
Trial Timeline
Aug 1, 2008 → Jan 1, 2010
NCT ID
NCT00572910About Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)
Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) is a phase 2 stage product being developed by Merck for Staphylococcus Aureus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00572910. Target conditions include Staphylococcus Aureus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00572910 | Phase 2 | Completed |
Competing Products
12 competing products in Staphylococcus Aureus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| AZD7760 | AstraZeneca | Phase 1/2 | 41 |
| V710 + Placebo | Merck | Phase 2/3 | 65 |
| Daptomycin | Merck | Phase 2 | 52 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 51 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 22 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |